XML 29 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:    
Net loss $ (634,399) $ (20,964,819)
Adjustments to reconcile net loss to cash used in operating activities:    
Depreciation expense 380 3,554
Stock-based compensation expense 603,946 1,373,182
Non-cash interest expense 53,750 109,335
Non-cash gain on extinguishment of debt (234,802)
Non-cash loss (gain) on change in fair value of warrant liability (355,890) 2,892,189
Amortization of premium/discount on marketable investment securities 515,577 (2,616)
Changes in operating assets and liabilities:    
Accrued interest income (246,862) 16,131
Prepaid and other current assets (4,903,207) (115,371)
Accounts payable (307,878) 414,979
Accrued expenses (636,720) 1,205,140
Litigation settlement liability 1,500,000
Cash used in operating activities (4,411,303) (15,303,098)
Cash flows from investing activities:    
Purchases of fixed assets (7,591)
Purchases of marketable investment securities (48,422,806) (6,315,297)
Maturities of marketable investment securities 4,650,000 10,208,000
Cash provided by (used in) investing activities (43,780,397) 3,892,703
Cash flows from financing activities:    
Proceeds from debt 233,537
Debt repayments (3,333,333) (1,666,667)
Proceeds from stock option exercises 6,693
Proceeds from sale of common stock sold in equity offering 26,840,457 5,653,140
Proceeds from exercise of warrants 5,000 7,674,876
Net proceeds from sale of common stock through ATM 3,406,053 9,004,368
Cash provided by financing activities 26,924,870 20,899,254
Net increase (decrease) in cash and cash equivalents (21,266,830) 9,488,859
Cash, cash equivalents and restricted cash at beginning of period 24,217,382 14,728,523
Cash, cash equivalents and restricted cash at end of period 2,950,552 24,217,382
Supplemental disclosure of cash flow information:    
Interest paid 149,543 276,019
Income taxes paid 200 200
Supplemental disclosure of non-cash investing and financing activities:    
Settlement of warrant liability on warrant exercises 18,365 6,313,338
Unrealized net gain (loss) on marketable investment securities (18,016) 38
Accrued final payment charge on debt $ 53,750 $ 109,335